• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GALDERMA QMED RESTYLANE-L IMPLANT, DERMAL, FOR AESTHETIC USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GALDERMA QMED RESTYLANE-L IMPLANT, DERMAL, FOR AESTHETIC USE Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Erythema (1840); Occlusion (1984); Pain (1994); Skin Discoloration (2074); Discharge (2225); Discomfort (2330); Numbness (2415); No Code Available (3191)
Event Date 11/06/2017
Event Type  Injury  
Manufacturer Narrative
Manufacturer narrative: lot number was not reported and trending on batch cannot be performed. Pharmacovigilance comment: the serious event of vascular occlusion and the non-serious events of hypoaesthesia, erythema, pain, discomfort, induration, discoloration, wound and discharge were considered expected and possibly related to the treatment. The seriousness criteria included the need for urgent medical intervention in the emergency room, multiple hyaluronidase injections and wound care clinic visits. Potential contributory factors for vascular occlusion include the injection procedure. Potential etiology for the remaining events includes injection site ischemia, and a wound associated with infection or necrosis. The case met the criteria for expedited reporting to regulatory authority. Engineering evaluation: the events are addressed in the labeling. No action is required. (b)(4).
 
Event Description
(b)(4) is a spontaneous report sent on 12-nov-2017 and a follow-up on 13-nov-2017 by a registered nurse (rn) which refers to a female (b)(6). Medical history, concomitant treatments, and allergies were not reported. The patient had previously received treatment with unspecified restylane products. On (b)(6) 2017, the patient received treatment with an unknown amount of restylane-l (lot unknown) to the nasolabial folds with an unknown needle type and unknown injection technique. On (b)(6) 2017, the patient experienced a vascular occlusion (vascular occlusion). One day later, on (b)(6) 2017, the patient experienced discomfort(injection site discomfort) at the nasolabial fold. On (b)(6) 2017, the patient experienced numbness (implant site hypoaesthesia), pain to touch (implant site pain), hardness(implant site induration) and bluish discoloration (implant site discoloration) at the nasolabial fold. 1. 5 vials of hyaluronidase[hyaluronidase] was administered to the injection site. On (b)(6) 2017, the patient was seen by the hcp with the same complaints that were improving, but ongoing. A second treatment of 1. 5 vials of hyaluronidase was administered. On (b)(6) 2017, the patient experienced redness(implant site erythema) with a wound(wound) that was oozing(injection site discharge) at the nasolabial fold. Treatment for the adverse event included hyaluronidase: 1. 5 vials of hyaluronidase on (b)(6) 2017, 1. 5 vials of hyaluronidase on (b)(6) 2017 and 1. 5 vials of hyaluronidase on (b)(6) 2017. The patient was referred to urgent care, went to the emergency room on (b)(6) 2017 and was referred to a wound care clinic. Outcome at the time of the report: vascular occlusion was not recovered/not resolved. Discomfort was not recovered/not resolved. Numbness was not recovered/not resolved. Pain to touch was not recovered/not resolved. Hardness was not recovered/not resolved. Redness was not recovered/not resolved. Wound was not recovered/not resolved. Oozing was not recovered/not resolved. Bluish discoloration was not recovered/not resolved.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameRESTYLANE-L
Type of DeviceIMPLANT, DERMAL, FOR AESTHETIC USE
Manufacturer (Section D)
GALDERMA QMED
seminarigatan 21
upsala, se-752 28 SE-75 2 28
SW SE-752 28
Manufacturer Contact
lisa bernaise
seminarigatan 21
upsala, se-752 28 SE-75-2 28
SW   SE-752 28
MDR Report Key7041137
MDR Text Key92475333
Report Number9710154-2017-00097
Device Sequence Number1
Product Code LMH
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P040024/S039
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Reporter Occupation
Type of Report Initial
Report Date 11/17/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/17/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator
Was Device Available for Evaluation? No Answer Provided
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? Yes
Date Report Sent to FDA11/17/2017
Distributor Facility Aware Date11/12/2017
Event Location No Information
Date Report to Manufacturer11/12/2017
Date Manufacturer Received11/12/2017
Was Device Evaluated by Manufacturer? No Answer Provided
Is the Device Single Use? No Answer Provided
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage

Patient Treatment Data
Date Received: 11/17/2017 Patient Sequence Number: 1
-
-